366 related articles for article (PubMed ID: 24074784)
21. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Aihara T; Takatsuka Y; Ohsumi S; Aogi K; Hozumi Y; Imoto S; Mukai H; Iwata H; Watanabe T; Shimizu C; Nakagami K; Tamura M; Ito T; Masuda N; Ogino N; Hisamatsu K; Mitsuyama S; Abe H; Tanaka S; Yamaguchi T; Ohashi Y
Breast Cancer Res Treat; 2010 Jun; 121(2):379-87. PubMed ID: 20390343
[TBL] [Abstract][Full Text] [Related]
22. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
23. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
24. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
25. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
[TBL] [Abstract][Full Text] [Related]
26. Update on adjuvant hormonal treatment of early breast cancer.
Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
[TBL] [Abstract][Full Text] [Related]
27. Initialization of adjuvant hormonal treatment for breast cancer.
Martínez Guisado A; Sánchez Muñoz A; de la Cabeza Lomas Garrido M; Ruíz Borrego M; Bayo Calero J; de Toro Salas R; González Mancha R; de la Haba Rodríguez J; Alba Conejo E
Adv Ther; 2011 Sep; 28 Suppl 6():66-84. PubMed ID: 21922396
[TBL] [Abstract][Full Text] [Related]
28. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Ewer MS; Glück S
Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
[TBL] [Abstract][Full Text] [Related]
29. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
30. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
[TBL] [Abstract][Full Text] [Related]
31. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
32. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Henry NL; Giles JT; Stearns V
Oncology (Williston Park); 2008 Nov; 22(12):1401-8. PubMed ID: 19086600
[TBL] [Abstract][Full Text] [Related]
33. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
34. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
35. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Higgins MJ; Liedke PE; Goss PE
Crit Rev Oncol Hematol; 2013 Apr; 86(1):23-32. PubMed ID: 23116626
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Seo JH; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
[TBL] [Abstract][Full Text] [Related]
37. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
38. Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
Prescrire Int; 2005 Apr; 14(76):43-4. PubMed ID: 15875334
[TBL] [Abstract][Full Text] [Related]
39. Letrozole in the neoadjuvant setting: the P024 trial.
Ellis MJ; Ma C
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
[TBL] [Abstract][Full Text] [Related]
40. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
